stable coronary artery disease
-
Upload
magdy-elmasry -
Category
Health & Medicine
-
view
217 -
download
8
Transcript of stable coronary artery disease
![Page 1: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/1.jpg)
![Page 2: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/2.jpg)
WHAT SAY NEW GUIDELINES ?
Many alternatives for treating angina : How to choose ?
![Page 3: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/3.jpg)
![Page 4: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/4.jpg)
A new name for the Guidelines that can be applied to a wider and more realistic range of patients
“Stable angina pectoris”
2006“Stable Coronary Artery Disease”
2013
This much broader term intended to include both symptomatic
and asymptomatic patients with a previous or present history of confirmed or suspected stable CAD.
![Page 5: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/5.jpg)
(i) Those having stable angina pectoris or other symptoms felt to be related to CAD such as dyspnoea
(ii) Those previously symptomatic with known obstructive or non-obstructive CAD, who have become asymptomatic with treatment and need regular follow-up
(iii) Those who report symptoms for the first time and are judged to already be in a chronic stable condition (for instance because history-taking reveals that similar symptoms were already present for several months).
Stable coronary artery disease
![Page 6: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/6.jpg)
![Page 7: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/7.jpg)
Meets all three of the following characteristics:
• substernal chest discomfort of characteristicquality and duration;• provoked by exertion or emotional stress;• relieved by rest and/or nitrates within minutes.
Typical angina
Meets two of these characteristicsAtypical angina(probable)
Lacks or meets only one or none of thecharacteristics
Non-anginalchest pain
(Definite)
Traditional clinical classification of chest pain
![Page 8: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/8.jpg)
Ordinary activity does not cause angina such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation.
Class I
Slight limitation of ordinary activity. Angina on walking or climbing stairs rapidly, walking or stair climbing after meals, or in cold, wind or under emotional stress, or only during the first few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.
Class II
Marked limitation of ordinary physical activity. Angina on walking one to two blocks (~100–200 m)on the level or one flight of stairs in normal conditions and at a normal pace.
Class III
Inability to carry on any physical activity without discomfort' –angina syndrome may be present at rest'.
Class IV
Classification of angina severity according to the Canadian Cardiovascular Society
![Page 9: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/9.jpg)
Antianginal Drug
Relief of symptoms Improving prognosis
(Prevent cardiovascular events)
Feel better Live longer
![Page 10: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/10.jpg)
Medical management of SCAD patients
“We recommend the old drugs as first line treatment because they are cheap, effective and available everywhere.”
“We have roughly the same level of evidence for all of the second line drugs and we recommend that physicians also choose according to what is available in their country.”
Angina relief Event prevention
• β-blockers and/or CCB
Ivabradine Long-acting nitrates Nicorandil Ranolazine Trimetazidine
• Lifestyle management• Control of risk factors
• Aspirin (if intolerance, consider clopidogrel)
• Statins• Consider ACE inhibitors or ARBs
+ consider angio → PCI-stenting or CABG
Short-acting nitrates, plus
1st line
2nd line
![Page 11: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/11.jpg)
Medical management of SCAD patients
Angina relief Event prevention
• β-blockers and/or CCB
IvabradineLong-acting nitratesNicorandilRanolazineTrimetazidine
• Lifestyle management• Control of risk factors
• Aspirin (if intolerance, consider clopidogrel)
• Statins• Consider ACE inhibitors or ARBs
+ consider angio → PCI-stenting or CABG
Short-acting nitrates, plus
1st line
2nd line
About revascularization, chairmen hopes that “guidelines will shift physicians’ practice so that they consider optimal medical treatment as their first course of action in stable CAD patients”.
![Page 12: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/12.jpg)
Stable coronary artery disease
Old and New Anti-anginalDrugs
![Page 13: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/13.jpg)
Old ( traditional ) anti-anginals
Drug class Vasodilation Heart rate Myocardial
contractility
Short acting
nitrate -
sublingual
Beta-blockers
Long-acting
nitrates
Calcium channel
blockers
DHP Amlodipine Non-DHP Diltiazem and Verapamil
![Page 14: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/14.jpg)
NitratesCalcium channel blockers
Beta blockersCalcium channel blockers
![Page 15: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/15.jpg)
New mechanistic approaches to myocardial ischemia
Metabolic modulation (trimetazidine)
Sinus node inhibition (ivabradine)
Late Na+ current inhibition (ranolazine)
Preconditioning (nicorandil)
![Page 16: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/16.jpg)
Metabolic modulation (pFOX ) : trimetazidine
Trimetazidine : pFOX (partial fatty acid oxidation ) inhibitor
![Page 17: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/17.jpg)
![Page 18: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/18.jpg)
Ischemic Preconditioning
Myocardial Protection
There is general consensus that
Mito K+ATP channels
play a key role
![Page 19: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/19.jpg)
Focus on ATP-sensitive K+ channels
![Page 20: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/20.jpg)
MYOCARDIAL ISCHAEMIC PRE-CONDITIONING
“Phenomenon by which a brief episode (s) of myocardial ischaemia increases the ability of the heart to tolerate a sbsequent prolonged period of ischaemia”
![Page 21: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/21.jpg)
IPC concept
Murry CE. Circulation 1986;74:1124-36
infarct surface
ControlGroup
PreconditioningGroup
ischemia
brief ischemia
ischemia
reperfusioninduction
prolonged occlusion
![Page 22: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/22.jpg)
Adenosine subtype 1 (A1) receptor
Ischemic stimulus
G protein and protein kinase C (PKC).
Opening of Mito K+ATP channel
Cardio-protective effect
IPC involves a complex cascade of intracellular events
amplified
effector
?
![Page 23: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/23.jpg)
Cardioprotective effect
Opening Mitochondrial ATP-K+ channels:
Mimic the cardioprotective effect of IPC without inducing ischemia
Pharmacological preconditioning agents
Nicorandil mimics IPC
![Page 24: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/24.jpg)
Preconditioning: Nicorandil
Nitrate-associated effects
• Vasodilation of coronary epicardial arteries
Activation of ATP-sensitive K+ channels
• Ischemic preconditioning
• Dilation of coronary resistance arterioles
N O
O NO2
HN
![Page 25: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/25.jpg)
Nicorandil :dual effects
The ATP-sensitive K+ channels are composed of subunit proteins: *an inwardly rectifying K+ channel (KIR) *a sulphonylureareceptor (SUR)
Activation of ATP-sensitive K+ channels causes K+ efflux and hyperpolarisation of the smooth muscle cell membrane and closure of voltage-gated Ca2+ channels.Closure of Ca2+ channels reduces intracellular levels of Ca2+, resulting in relaxation of vascular smooth muscle and dilation of systemic and coronary arterioles
The nitrate moiety produces relaxation of vascular smooth muscle with dilation of systemic venous circulation and epicardial coronary arteries.
![Page 26: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/26.jpg)
EFFECT OF MEDICATION
Preconditioning Preconditioning
KATP channel blockersKATP channel openers
Sulfonylurea drugs:
Glibenclamide , gliclazide , glimepiride
NICORANDIL
![Page 27: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/27.jpg)
Cardioprotective effects of nicorandil
![Page 28: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/28.jpg)
![Page 29: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/29.jpg)
Adverse effects
Blood pressure and heart rate
Comorbidities & Contraindications
Drug costs & Drug-drug interactions
The ESC common strategy might be adjusted according to:-
![Page 30: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/30.jpg)
Anti-anginal drugs.
![Page 31: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/31.jpg)
Anti-anginal drugs.
![Page 32: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/32.jpg)
Short-Acting NitratesSL Nitroglycerin & SL Isosorbide dinitrate
• Relief of pain, hemodynamic effect (10 mm Hg drop, ↑HR)
• Onset: 1-3 min, duration:10-30 min
• Prevention of attack: To be taken 5-10 min before the exertion that possibly precipitate angina(activity after a meal, emotional stress, sexual activity and in colder weather)
• Instructions to Patient:
o Sit immediately, place NTG/ISDN tablet under tongue
(standing promotes syncope, lying down enhances venous return and heart work)
o Max three tablets over 15 min
o If pain persists >30 min →suspected ACS
![Page 33: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/33.jpg)
Nitrate Tolerance Minimization
• Nitrate-free interval of 10-12 hours minimize tolerance to therapeutic activity
• Lowest effective nitrate dose lower tolerance
• ß-blocker or CCB is given to provide anginalprotection during nitrate-free period
• Long-acting nitrates have no evidence of causing tolerance to SL nitrates’ use
![Page 34: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/34.jpg)
ISOSORBIDE DINITRATE & MONONITRATE (ISDN & ISMN)
• ISDN oral formulation is used usually three times a day especially in severe angina
Usually ISDN is taken at 7 AM, Noon & 5 PM to allow 12 hr nitrate-free period
ISDN can be given twice/day in moderate severity angina
• ISMN can be given once or twice/day
(early morning & 7 hrs later)
ISMN has better patient compliance
![Page 35: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/35.jpg)
Sexual activity may trigger ischaemia, and nitroglycerin prior to sexual intercourse may be helpful as in other physical activity.
Sexual activity
Erectile dysfunction (ED)
Pharmacological therapy with PDE5 inhibitors (sildenafil, tadalafil and vardenafil) are effective,safe and well tolerated in men with stable CAD
![Page 36: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/36.jpg)
All of the preparations of nitroglycerin as well as isosorbide mononitrate and isosorbide dinitrate, are absolute contra-indications to the use of PDE5 inhibitors because of the risk of synergistic effects on vasodilation, causing hypotension and haemodynamic collapse.
If a patient on a PDE5 inhibitor develops chest pain, nitrates should not be administered in the first 24 hours (sildenafil “viagra”, vardenafil “levitra”) to 48 hours (tadalafil “cialis”).
![Page 37: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/37.jpg)
Prostatic problems
Erectile dysfunction
Angina
α-adrenergic blockers
PDE5 inhibitorsNitrates
![Page 38: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/38.jpg)
β-Adrenergic Blockers
ß-blockers abrupt withdrawal can be serious in severe CAD → ACS
*β - Blockers can be combined with CCBs ( DHPs:amlodipine ) to control angina.*Combination therapy of β -blockers with verapamil and diltiazem(non-DHPs) should be avoided because of the risk of bradycardia or AV block
Nevibolol and bisoprolol are partly secreted by the kidney, whereas carvedilol and metoprolol are
metabolized by the liver, hence being safer in patients with renal compromise.
![Page 39: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/39.jpg)
Anti-anginal drugs should be started at very low doses, with preferential use of drugs with
no- or limited impact on BP, such as ivabradine (in patients with sinus rhythm),
ranolazine or trimetazidine.
![Page 40: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/40.jpg)
Although lowering the heart rate ,60 b.p.m. is an important goal in the treatment of SCAD, patients presenting with low heart rate should be treated differently.
Heart rate lowering drugs (β-blockers, ivabradine,heartrate lowering CCBs) should be avoided or used with caution and, if needed, started at very low doses.
Anti-anginal drugs without heart lowering effects should preferably be given.
![Page 41: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/41.jpg)
Non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with an increased risk for CV events
In patients at increased CV risk in need of pain relief, it is therefore recommended to commence with acetaminophen or aspirin at the lowest efficacious dose, especially for short-term needs.
If adequate pain relief requires the use of NSAIDs, these agentsshould be used in the lowest effective doses and for the shortest possible duration.
![Page 42: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/42.jpg)
![Page 43: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/43.jpg)
BIShort-acting nitrates are recommended
AIFirst-line treatment is indicated with ß-blockers and/or calcium channel blockers to control heart rate and symptoms.
BIIaFor second-line treatment it is recommended to add long-acting nitrates or ivabradine or nicorandil or ranolazine,according to heart rate, blood pressure and tolerance.
BIIbFor second-line treatment, trimetazidine may be considered
CIAccording to comorbidities/tolerance it is indicated to use second-line therapies as first-line treatment in selected patients
Angina/ischaemia relief Class Level
2013 ESC guidelines on the management of SCAD
![Page 44: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/44.jpg)
AILow-dose aspirin daily is recommended in all SCAD patients.
BIClopidogrel is indicated as an alternative in case of aspirin intolerance.
AIStatins are recommended in all SCAD patients.
AIIt is recommended to use ACE inhibitors (or ARBs) if presence of other conditions (e.g. heart failure, hypertension or diabetes).
Event prevention Class Level
2013 ESC guidelines on the management of SCAD
![Page 45: stable coronary artery disease](https://reader034.fdocuments.net/reader034/viewer/2022042615/55a974581a28abd22a8b479c/html5/thumbnails/45.jpg)